Showing 20 of 120 recruiting trials for “Small cell lung cancer”
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
👨⚕️ Lei Deng, MD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College📍 1 site📅 Started Aug 2025View details ↗
Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
RecruitingNCT07309211 ↗
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
🏥 The First Affiliated Hospital with Nanjing Medical University📍 4 sites📅 Started Jul 2025View details ↗
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
RecruitingNCT07498933 ↗
FAP-targeted PET/NIR in Lung Malignant Tumors
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RecruitingNCT06486428 ↗
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
👨⚕️ Christine Lovly, MD PhD, Vanderbilt-Ingram Cancer Center, Nashville, TN📍 52 sites📅 Started May 2025View details ↗
Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer
👨⚕️ Ying Yuan, Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started May 2025View details ↗
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
🏥 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)📍 11 sites📅 Started Mar 2025View details ↗
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
👨⚕️ Melissa Johnson, MD, SCRI Development Innovations, LLC📍 30 sites📅 Started Mar 2025View details ↗
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
RecruitingNCT06717243 ↗
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
👨⚕️ Hui Liu, Professor, Sun yat-sen universtiy cancer center📍 1 site📅 Started Nov 2024View details ↗
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →